Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Giulia Stella (Pavia, Italy), Giulia Stella, Rebecca Senetta, Michele Zorzetto, Simona Inghilleri, Ludovica Verdun Di Cantogno, Paolo Comoglio, Paola Cassoni, Federica Meloni. MET genetic lesions in NSCLC are functional markers of early hematogenous spreading and radioresistance. Eur Respir J 2015; 46: Suppl. 59, 540

Member's Comments

No comment yet.

Related content which might interest you: Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor? Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 MET genetic lesion in pleural tumor of unknown primary origin. A preliminary report Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prognostic impact of secondary malignancies in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Abnormal abundance of senescent fibroblasts in the tumor stroma of non-small cell lung cancer patients Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Prognostic factors in non-small cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome in resected non-small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014